Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Merck |
---|---|
Information provided by: | Merck |
ClinicalTrials.gov Identifier: | NCT00543010 |
A study to evaluate the cardiac and metabolic effects of MK0767 in patients with Type 2 Diabetes.
This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).
Condition | Intervention | Phase |
---|---|---|
Diabetes Mellitus, Type 2 |
Drug: MK0767 |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study |
Ages Eligible for Study: | 21 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 2007_644 |
Study First Received: | October 5, 2007 |
Last Updated: | October 11, 2007 |
ClinicalTrials.gov Identifier: | NCT00543010 |
Health Authority: | United States: Food and Drug Administration |
Glipizide Metabolic Diseases Diabetes Mellitus, Type 2 Diabetes Mellitus |
Endocrine System Diseases Endocrinopathy Metabolic disorder Glucose Metabolism Disorders |